UK Biotech company Genflow Biosciences is set to make its London debut amidst a whirlwind of global interest in the emerging longevity market.
You can grab a copy of the full white paper report on Genflow HERE
Challenging the ageing process
Genflow’s CEO, Dr Eric Leire and his team are working towards a cutting-edge treatment designed to challenge the ageing process and give a significant boost to longevity and latter-year wellness in both humans and dogs.
The therapy works on 4 out of the 9 hallmarks for ageing and utilises the Sirtuin-6 (SIRT-6) gene variant found in centenarians.
With patent protection already secured along with an exclusive license agreement, Genflow is now primed and ready to enter pre-clinical trials to develop its ground-breaking treatment and compete with similar BioTech newcomers state-side.
With a whole host of contributing factors to Genflow’s value proposition, the company is looking to leverage the following facets of the Healthspan and Lifespan market opportunity.
- Age-related diseases are fast becoming more prevalent amidst an older global population. According to UN statistics, one quarter of the world’s population will be over 65 years old by 2100. This in turn will bring greater focus to the importance of improving quality of life in later years
- Unless treatments are introduced to treat age-related diseases, more people will spend longer suffering from ill-health
- The top-four causes of ill-health and subsequently death in humans are Cardiovascular disease, Cancer, Dementia and Respiratory Diseases – all of which show a strong increase with ages, thus highlighting the need for medical science to shift it’s focus towards treatment of these age-related illnesses.
- According to the world health organisation, the current market is worth just under US$ 2trillion and the cultural shift towards addressing a resolution to the ageing dilemma means that first movers in the space currently enjoy a wide open playing field in which to gain market share.
LSE Listing and first-mover advantage
Genflow will make its LSE debut in Q1 of 2022 with a listing price of 8.0 and a target price post-listing of 16.0. This is due in part to the fact that Genflow will be the first longevity focused company to list in Europe.
Looking at Genflow’s peer group who are mainly listed in the United States and are mostly at similar, pre-revenue and early-revenue development stages, the average market capitalisation is £166m. Genflow is coming on with a valuation of circa £20m.
Below we can see a snapshot of these US based competitors which serves to better demonstrate the significant gap between the value of these state-side BioTech innovators and Genflow’s fledgling business.
When we take these two contributing factors into account, it is easy to see why Genflow’s imminent listing has attracted significant levels of interest from prominent investors.
Not least of which is the UK’s answer to Warren Buffet, Isle-of-Man based investor and philanthropist Jim Mellon.
Jim Mellon as an early backer of Genflow
As one of the UK’s most prolific and high-profile investors, the introduction of Jim Mellon into the investor mix has certainly started to turn heads in the direction of Genflow. He currently owns just over 1% of the company and he recently held a week-long conference specifically relating to Longevity.
- Involved in BioTech for over 30 years
- Held Senior positions including CEO of publicly traded companies
- Successes include Enochian (NASDAQ:ENOB), a gene-modified cell therapy company
- M Pharm, PhD, IP
- Functional Medicine Specialist
- Anticancer research scientist
- Various distinctions and publications in peer-reviewed academic journals
The current Longevity trend & Bezos’ Altos
Altos Labs are now at the forefront of the migration towards Longevity by big name players across the pond and have refocused the attention of the wider investing world.
Jeff Bezo’s newest venture is set to pursue biological reprogramming technology in the hopes of rejuvenating cells in animal bodies. It is thought that this will then lead to their revitalisation, and ultimately to prolongment of human life.
Altos joins the new wave of BioTech emerging in California, spearheaded back in 2013 by Google’s Larry Page with Calico Labs.
Needless to say, Genflow is in a highly sought after position being the very first company of it’s kind to win the title of ‘first to float’ across the entirety of Europe.
The move towards clinical trials of its patented technology should also see Genflow being first to production and consequently first to market with it’s health enhancing and life extending offering.
It could take years for big pharma to develop a gene therapy to slow the ageing process, but much less for them to scoop up Genflow. This consequently makes the company a ripe candidate for a major exit and adds an additional layer of excitement for early stage investors.
More from Clear Capital Markets…
Clear Capital Markets and their Corporate Broking team are proud to have been the sole broker in the fundraising for Genflow, which has in turn lead to their clients getting early access to the opportunity.
Genflow sits alongside 9 other IPOs that Clear Capital Markets have brought to their clients as either Corporate Broker or Placing Agent in 2021, and the year ahead is already promising a host of exciting new issues.
If you currently managing your own portfolio and would like more information on how to introduce IPOs and Secondary placings into your investment mix, you can speak to someone in our Private Client Investment team using the details below:
Clear Capital Markets.
Private Client Investment Team
Tel: 0203 869 6080
Trading in equities may not be suitable for all investors. The value of investments may fall, and you may get back less than you invested. an investment’s past performance is not a guarantee of future performance. Investments in pre-IPO’s and IPO’s involve a high degree of risk and are not suitable for all investors. Small Cap companies can be volatile and are considered high risk investments. Capital invested is at risk.
Tax allowances depend on personal circumstances. Before you trade you should obtain details of all commissions and charges. You should make sure you can afford any potential losses before you trade. Make sure you fully understand the risk involved and if you are in any doubt seek independent and professional advice.
Clear Capital Markets Ltd of Broadgate Tower, 12th Floor, Office 1213, 20 Primrose Street, London, EC2A 2EW are authorised and regulated by the Financial Conduct Authority No 706689.